wherein said anti-TFPI antibody formulation has a pH of 5.5.

7. The use of a therapeutically effective amount of a formulation of claim 1 in the manufacture of a medicament for the treatment of hemophilia A or hemophilia B in a patient.

8. The use of claim 7 wherein the medicament is to be administered intravenously, subcutaneously, or intramuscularly.